The objectives pursued by this project are two. First, validate the potential of the consortium’s proprietary antibodies in early diagnosis in Alzheimer’s patients. Second, obtain a first proof of concept that confirms the viability and efficacy of an immunotherapy based on those antibodies.
- RESEARCH TYPE Functionalization of biosensors
- RESEARCH YEAR 2020
The challenge of this project is to improve the performance of our biosensors, to improve their range and effectiveness for detecting different biomarkers, keeping them label-free and providing quantitative information through a simple and low-cost measurement system. This project is a great opportunity to achieve true technological innovation in the market through research, bringing together two traditionally separated worlds that urgently need to complement each other.
The biofunctionalization of a biosensor is the process of immobilization of a molecule on its surface, with great affinity and specificity to the analyte to be detected. The execution of this process in a homogeneous and stable way is key to improve the sensitivity of the biosensors. That allows the detection of low concentrations of biomarkers of different diseases, even before their symptoms appear. An early diagnosis is crucial to improve the effectiveness of treatments and the quality of life of those affected and their families.
This research project consists in the development of new biofunctionalization protocols of our label-free optical biosensor, so that it is able to detect different biomarkers related to various diseases, including Alzheimer’s. These new protocols will consist of making modifications to the functional groups of the biosensor surface material, thus facilitating the union between said material and the bioreceptors. As a surface modification strategy, this project focuses on different silanization protocols, which may be used for the immobilization of different bioreceptors.